Empiric antibiotic use and de-escalation practices incommunity-acquired infections in adults: a retrospectiveobservational study at a tertiary care hospital in UAE

Main Article Content

Alla Laila
Juny Sebastian

Keywords

Anti-Bacterial Agents, Antimicrobial stewardship, Community-Acquired Infections, Pneumonia, Sepsis, Urinary Tract Infection, United Arab Emirates

Abstract

Background: The increase in antimicrobial resistance (AMR) rates is a global burden, including the Middle East and Gulf Region. Gaining insight into antibiotic use patterns in the United Arab Emirates (UAE) is crucial for informing antimicrobial strategies, such as antibiotic de-escalation, which can play a key role in reducing AMR. Methods: This retrospective observational study collected data from a tertiary care hospital medical record. Eligible patients were adults admitted for management of Community Acquired Pneumonia (CAP), Urinary Tract Infections (UTI), or sepsis between January 2022 and December 2023. Patients’ characteristics such as demographics, comorbidities and severity of infection on admission, treatment received during hospital stay and clinical outcomes were recorded in a suitably designed data collection form. The pattern of antibiotic prescription was analyzed and the rate of empiric broad-spectrum use was evaluated. Eligibility for de-escalation was assessed based on microbiological results. Data analysis was conducted using Stata/SE 12.0 For windows and Microsoft Excel for windows. Results: Data from 207 patients (median age 41) showed that 45.4% had CAP, 40.1% UTI, 14.5% sepsis. Overall, 96 patients (46.4%) had culture specimens obtained pre-treatment. Among CAP and sepsis patients, positive cultures were observed in only 8 cases. Conversely, in UTI patients, 32 cultures were positive, with 28 identifying E. coli as the pathogen, 12 of which were ESBL-producing strains. Broad-spectrum antibiotics were initiated in 70.5% of patients, with meropenem being the most commonly prescribed (57.9%). Of 27 de-escalation- eligible patients, 25.9% were successfully de-escalated. Broad-spectrum prescribing was associated with recent intravenous antibiotic exposure, admission to the Intensive care unit (ICU) and higher C-reactive protein (CRP) levels. The odds of prescribing a broad-spectrum antibiotic increase by 1% for each unit increase in CRP level. The interquartile range (IQR) for duration of hospitalization was 3- 5 days. Successful therapy was achieved in 197 cases. Conclusion: Broad-spectrum antibiotics were frequently initiated empirically, with meropenem being the most common choice. While microbiological data supported de-escalation in 27 cases, it occurred in only a quarter of these. Opportunities exist to optimize empiric therapy and promote antibiotic stewardship strategies such as de-escalation.

Abstract 17 | PDF Downloads 2

References

1. GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet. 2024;404(10459):1199-1226. doi:10.1016/S0140-6736(24)01867-1
2. Ministry of Health and Prevention (UAE). National AMR surveillance report 2022 [Internet]. Dubai: Ministry of Health and Prevention; 2022 [cited 2024 Apr 22]. Available from: https://mohap.gov.ae/assets/f5a5705/National%20AMR%20 Surveillance%20Report%202022%20MOHAP_638205230312192483.pdf.aspx.
3. O’Neill J. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations [Internet]. London: Review on Antimicrobial Resistance; 2014 Dec [cited 2024 Sep 21]. Available from: https://amr-review.org/sites/default/files/AMR%20 Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf.
4. World Health Organization. Antimicrobial Stewardship Programmes In Health-Care Facilities In Low-And Middle-Income Countries: a WHO practical toolkit. [Internet]. Geneva: WHO; 2019 Oct [cited 2024 Sep 21]. Available from: https://www.who. int/publications/i/item/9789241515481.
5. Bo L, Sun H, Li YD, Zhu J, Wurpel JND, Lin H, et al. Combating antimicrobial resistance: the silent war. Front Pharmacol. 2024 Feb 14;15:1347750. doi: 10.3389/fphar.2024.1347750. PMID: 38420197; PMCID: PMC10899355.
6. Alawi MM, Darwesh BM. A stepwise introduction of a successful antimicrobial stewardship program. Experience from a tertiary care university hospital in Western, Saudi Arabia. Saudi Med J. 2016 Dec;37(12):1350-1358. doi: 10.15537/smj.2016.12.15739. PMID: 27874151; PMCID: PMC5303774.
7. Mahboub B, Al Zaabi A, Al Ali OM, Ahmed R, Niederman MS, El-Bishbishi R. Real life management of community-acquired Pneumonia in adults in the Gulf region and comparison with practice guidelines: a prospective study. BMC Pulm Med. 2015 Sep 30;15:112. doi: 10.1186/s12890-015-0108-x. PMID: 26424530; PMCID: PMC4591061.
8. Al-Tawfiq JA, Momattin H, Hinedi K. Empiric Antibiotic Therapy in the Treatment of Community-acquired Pneumonia in a General Hospital in Saudi Arabia. J Glob Infect Dis. 2019 Apr-Jun;11(2):69-72. doi: 10.4103/jgid.jgid_84_18. PMID: 31198310; PMCID: PMC6555230.
9. Alshareef H, Alfahad W, Albaadani A, Alyazid H, Talib RB. Impact of antibiotic de-escalation on hospitalized patients with urinary tract infections: A retrospective cohort single center study. J Infect Public Health. 2020 Jul;13(7):985-990. doi: 10.1016/j. jiph.2020.03.004. Epub 2020 Apr 8. PMID: 32276874.
10. Webb BJ, Sorensen J, Jephson A, Mecham I, Dean NC. Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study. Eur Respir J. 2019 Jul 4;54(1):1900057. doi: 10.1183/13993003.00057-2019. PMID: 31023851.
11. Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018 Aug 20;7(11):e1507670. doi: 10.1080/2162402X.2018.1507670. PMID: 30377571; PMCID: PMC6205076.
12. Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014 Jan;40(1):32-40. doi: 10.1007/s00134-013-3077-7. Epub 2013 Sep 12. PMID: 24026297.
13. Gil R, Webb BJ. Strategies for prediction of drug-resistant pathogens and empiric antibiotic selection in community-acquired pneumonia. Curr Opin Pulm Med. 2020 May;26(3):249-259. doi: 10.1097/MCP.0000000000000670. PMID: 32101906.
14. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015 Jul 30;373(5):415-27. doi: 10.1056/NEJMoa1500245. Epub 2015 Jul 14. PMID: 26172429; PMCID: PMC4728150.
15. Self WH, Wunderink RG, Williams DJ, Zhu Y, Anderson EJ, Balk RA, et al. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clin Infect Dis. 2016 Aug 1;63(3):300-9. doi: 10.1093/cid/ciw300. Epub 2016 May 8. PMID: 27161775; PMCID: PMC4946021.
16. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community- acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. PMID: 31573350; PMCID: PMC6812437.
17. Infectious Diseases Society of America. Clinical pathway for managing community-acquired pneumonia (CAP) in adults [Internet]. 2024 [cited 2024 Aug 17]. Available from: https://www.idsociety.org/globalassets/idsa/practice-guidelines/ community-acquired-pneumonia-in-adults/cap-clinical-pathway-final-online.pdf.
18. Ministry of Health and Prevention (MOHAP). Open data: National AMR Surveillance Report 2022 [Internet]. 2022 [cited 2024 August 15]. Available at: https://mohap.gov.ae/en/open-data/mohap-open-data.
19. Ministry of Health and Prevention (MOHAP). Open data: National AMR Surveillance Report 2019 [Internet]. 2019 [cited 2024 August 15]. Available at: https://mohap.gov.ae/en/open-data/mohap-open-data.
20. Rhee C, Chen T, Kadri SS, Lawandi A, Yek C, Walker M, et al. Trends in Empiric Broad-Spectrum Antibiotic Use for Suspected Community-Onset Sepsis in US Hospitals. JAMA Netw Open. 2024 Jun 3;7(6):e2418923. doi: 10.1001/jamanetworkopen.2024.18923. PMID: 38935374; PMCID: PMC11211962.
21. Worldwide Antimicrobial Resistance National/International Network Group (WARNING) Collaborators. Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action. World J Emerg Surg. 2023 Oct 16;18(1):50. doi: 10.1186/ s13017-023-00518-3. PMID: 37845673; PMCID: PMC10580644.
22. Mathieu C, Pastene B, Cassir N, Martin-Loeches I, Leone M. Efficacy and safety of antimicrobial de-escalation as a clinical strategy. Expert Rev Anti Infect Ther. 2019 Feb;17(2):79-88. doi: 10.1080/14787210.2019.1561275. Epub 2018 Dec 28. PMID: 30570361.
23. Rainess R, Campbell P, Santamala J, Kubin CJ, Mehta M. Outcomes Associated with De-escalation of Antibiotics to Target Positive Cultures when Treating Febrile Neutropenia. J Pharm Pract. 2024 Apr;37(2):301-306. doi: 10.1177/08971900221132120. Epub 2022 Oct 6. PMID: 36201023.
24. McWilliam S, Riordan A. How to use: C-reactive protein. Arch Dis Child Educ Pract Ed. 2010 Apr;95(2):55-8. doi: 10.1136/ adc.2009.174367. PMID: 20351152.
25. Petel D, Winters N, Gore GC, Papenburg J, Beltempo M, Lacroix J, et al. Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis. BMJ Open. 2018 Dec 22;8(12):e022133. doi: 10.1136/bmjopen-2018-022133. PMID: 30580258; PMCID: PMC6318522.
26. Boucherabine S, Nassar R, Mohamed L, Habous M, Nabi A, Husain RA, et al. Methicillin-Resistant Staphylococcus aureus: The Shifting Landscape in the United Arab Emirates. Antibiotics (Basel). 2025 Jan 2;14(1):24. doi: 10.3390/antibiotics14010024. PMID: 39858310; PMCID: PMC11759823.
27. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Executive Summary: Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016 May 15;62(10):1197-1202. doi: 10.1093/cid/ciw217. PMID: 27118828.